Trials / Completed
CompletedNCT02168738
Investigation of Docosahexaenoic Acid (DHA) Metabolic Pathway in Human by Using 13C Labeled Molecules
Bioavailability of DHA-TG (Docosahexaenoic Triglyceride), DHA-PC (Docosahexaenoic Phosphatidylcholine) and AcedoPC (1-acetyl-2-docosahexaenoic-glycerophosphocholine) in Human
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 4 (actual)
- Sponsor
- Hospices Civils de Lyon · Academic / Other
- Sex
- Male
- Age
- 60 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to compare three lipidic forms of DHA in their metabolic pathway in human by using 13C labeled molecules. The circulating form of DHA plays a major role in his cerebral incorporation. The aim of this research is to confirm that some lipidic forms are best carriers for the cerebral incorporation in studying 13C-DHA distribution in plasma lipids and blood cells.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 13-C labeled AceDoPC-DHA | Each subject will receive a single dose of either lipid sequentially (according to randomization) a triglyceride (TG-DHA), a phospholipid (PC-DHA) or acetylated lysophosphatidylcholine (AceDoPC) labeled with 13C. The dose contains 50 mg 13C-DHA. The wash-out period is four months |
| DRUG | 13-C labeled TG-DHA | Each subject will receive a single dose of either lipid sequentially (according to randomization) a triglyceride (TG-DHA), a phospholipid (PC-DHA) or acetylated lysophosphatidylcholine (AceDoPC) labeled with 13C. The dose contains 50 mg 13C-DHA. The wash-out period is four months |
| DRUG | 13-C labeled PC-DHA | Each subject will receive a single dose of either lipid sequentially (according to randomization) a triglyceride (TG-DHA), a phospholipid (PC-DHA) or acetylated lysophosphatidylcholine (AceDoPC) labeled with 13C. The dose contains 50 mg 13C-DHA. The wash-out period is four months |
Timeline
- Start date
- 2014-03-01
- Primary completion
- 2015-04-01
- Completion
- 2015-04-01
- First posted
- 2014-06-20
- Last updated
- 2025-12-19
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT02168738. Inclusion in this directory is not an endorsement.